{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.8","value":"-1.8"},{"groupId":"OG001","spread":"5.0","value":"-1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"271"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.9","value":"-3.9"},{"groupId":"OG001","spread":"7.4","value":"-3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"206"}],"units":"Participants"}],"title":"Pre-Mobilization"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.5","value":"-4.4"},{"groupId":"OG001","spread":"7.5","value":"-4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"title":"Cycle 5 Arm A / Post Auto-HSCT Arm B"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.7","value":"-4.7"},{"groupId":"OG001","spread":"6.5","value":"-2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"title":"Cycle 8 Arm A /Cycle 5 Arm B"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.9","value":"-3.7"},{"groupId":"OG001","spread":"6.4","value":"-2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"166"}],"units":"Participants"}],"title":"Maintenance Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.8","value":"-4.9"},{"groupId":"OG001","spread":"6.1","value":"-2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"2 years from baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.4","value":"-4.6"},{"groupId":"OG001","spread":"7.2","value":"-3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"title":"3 years from baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"365"}],"units":"Participants"}],"description":"The FACT/GOG-NTX assessment consists of 11 questions that are all used to construct 1 subscale to summarize symptoms of peripheral neuropathy, including sensory, motor, and auditory problems and cold sensitivity. (https://www.facit.org/measures/FACT-GOG-NTX) Each question has 4 possible responses from 0 (Not at all) to 4 (Very Much) which are reverse-scored and summed. This sum is then scaled by the number of questions answered by multiplying by 11 and then dividing by the number of questions that are non-blank, in order to keep all final scores proportional to one another even if some questions are left blank. The aggregate score ranges from 0 to 44, with higher scores indicating less neurotoxicity and lower scores indicating more neurotoxicity. Change from baseline is the difference","dispersionType":"Standard Deviation","groups":[{"description":"All participants received one cycle of Lenalidomide (R), bortezomib (V) and dexamethasone (D) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD Alone participants received five additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study. After finishing protocol-specified treatment, off-study salvage transplantation was recommended but not mandated for RVD Alone participants at relapse.\n\nRVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12","id":"OG000","title":"RVD Alone"},{"description":"All participants received one cycle of Lenalidomide (R), bortezomib (V) and dexamethasone (d) and then were randomized. All participants then received two additional RVD cycles, followed by stem-cell collection. RVD plus autologous stem cell transplant (ASCT) participants received high-dose melphalan (200 mg/m2, adjusted for ideal body weight) ASCT and, upon recovery (\\~day 60), two additional RVD cycles. Maintenance in both arms comprised daily lenalidomide 10 mg, escalated to 15 mg if tolerated, until disease progression, unacceptable toxicity, or withdrawal from treatment or study.\n\nAfter finishing protocol-specified treatment, RVD plus ASCT participants could undergo a second transplant.\n\nRVD cycle duration=21 days R: 25 mg oral on days 1-14 V: 1.3 mg per square meter of body surface area IV or subcutaneous on days 1, 4, 8, and 11 D: 20 mg oral (cycles 1-3) or 10 mg (cycles 4-8) on days 1, 2, 4, 5, 8, 9, 11, and 12","id":"OG001","title":"RVD Plus ASCT"}],"paramType":"MEAN","populationDescription":"The analysis population is comprised of all randomized participants who completed the assessment both at baseline and at the respective timepoint on treatment.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Baseline), Cycle 2, Pre-Mobilization, Cycle 5 Arm A / Post Auto-HSCT Arm B, Cycle 8 Arm A /Cycle 5 Arm B, Maintenance Day 1, 2 years from baseline, 3 years from baseline","title":"Change From Baseline on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX)","type":"SECONDARY","unitOfMeasure":"units on a scale"}